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 Patients: Male, 75-year old • Male, 23-year old • Male, 24-year old
 Final Diagnosis: COVID-19 pneumonia
 Symptoms: Fever • hypoxia • respiratory failure
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 Clinical Procedure: —
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 Objective: Unusual or unexpected effect of treatment
 Background: Icosapent ethyl, a form of eicosapentaenoic acid with anti-inflammatory activity, has been approved as an ad-
junctive treatment with statins in patients with hypertriglyceridemia. Icosapent ethyl is currently undergoing 
clinical trials to determine its anti-inflammatory effects in patients with coronavirus disease 2019 (COVID-19). 
This report describes 3 intensive care unit (ICU) patients with moderate to severe COVID-19 pneumonia treat-
ed with icosapent ethyl as part of their supportive care who had favorable outcomes.
 Case Reports: Case 1 was a 75-year-old man with a past medical history of hyperlipidemia, hypertension, type 2 diabetes 
mellitus, obesity, and benign prostatic hyperplasia. Case 2 was a 23-year old man with a past medical histo-
ry of type 2 diabetes mellitus and obesity. Case 3 was a 24-year old man with a history of autism. All cases of 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were confirmed from a nasopharyn-
geal swab using the Becton Dickinson nasopharyngeal reverse-transcription polymerase chain reaction. All pa-
tients in these cases were treated with a course of 2 g of icosapent ethyl twice a day by nasogastric tube.
 Conclusions: This report of 3 cases describes the use of icosapent ethyl as a component of supportive treatments in ICU pa-
tients with moderate to severe COVID-19 pneumonia. However, as of yet there are no evidence-based treat-
ments for SARS-CoV-2 infection from controlled clinical trials. The outcomes of ongoing clinical trials are await-
ed to determine whether icosapent ethyl has anti-inflammatory effects in patients with SARS-CoV-2 infection 
and which patients might benefit from the use of this adjunctive treatment.
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The new strain of coronavirus, labeled severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2), is at the heart of 
an ever-growing coronavirus disease 2019 (COVID-19) pan-
demic. In addition to the fact that more than 14 million con-
firmed cases have been reported, the actual burden of the 
virus has been shown to be underestimated; of the numer-
ous confirmed cases, there is a substantially greater amount 
of people that have actually been exposed or infected by the 
virus [1]. In recent studies, the actual immunopathogenesis 
and development of severe lung and occasional systemic dis-
ease after infection have been shown to closely follow the 
immune response. Specifically, research shows that corona-
virus expresses surface proteins that activate the NLRP3 in-
flammasome, subsequently activating caspases, interleukins 
(ILs), and causing the release of proinflammatory cytokines, 
thus inducing pyroptosis, a highly inflammatory mechanism 
of cell death when compared with the usual neat and orderly 
process of apoptosis [2,3]. Thus, the respiratory sequelae mor-
bidity commonly associated with SARS-CoV-2 infection are not 
solely caused by the viral infection itself, but also by an over-
activated inflammatory host immune response, marked by an 
overall increase in inflammatory markers [4,5]. By that logic, 
anti-inflammatory therapy may be a driving point in combat-
ing SARS-CoV2-related disease.
Indeed, such therapy involving corticosteroids and other immu-
nosuppressants has been proposed, and clinical trials are well 
underway [4,5]. One such ongoing clinical trial (NCT04412018) 
(with an estimated completion date of December 2020) address-
es the effects of icosapent ethyl on inflammatory biomarkers 
in individuals with COVID-19 by looking at outcome measures 
such as changes to high-sensitivity C-reactive protein (hs-CRP) 
and the neutrophil-lymphocyte ratio [6]. Currently, icosapent 
ethyl, a form of eicosapentaenoic acid, is indicated for the treat-
ment of hypertriglyceridemia in patients at risk for ischemic 
heart disease and as an adjunctive treatment with maximal-
ly tolerated doses of statin therapy [7,8]. Regulatory approv-
al for adjunctive treatment of hypertriglyceridemia has been 
supported by the findings from the ANCHOR (NCT01047501) 
and the MARINE (NCT01047683) trials, showing a reduction 
in inflammatory markers in treated patients [9–11]. Apart 
from treatment for hypertriglyceridemia, it has been shown to 
have continued anti-inflammatory activity, as determined by 
the measurement of certain biomarkers of inflammation [12].
Although there have been multiple studies performed concern-
ing icosapent ethyl’s anti-inflammatory activity in the treatment 
of hypertriglyceridemia, the mechanism of icosapent ethyl in 
dealing with COVID-19-induced inflammation remains spec-
ulative. One such hypothesis looks at the potential for icos-
apent ethyl to suppress tumor necrosis factor (TNF)-alpha 
and IL-1beta messenger ribonucleic acid expression in alveo-
lar macrophages from asthmatic individuals [13]. Another hy-
pothesis examines how inappropriate neutrophil activation 
can result in acute lung injury, and how Resolvin E1, a deriv-
ative of eicosapentaenoic acid, promotes neutrophil apopto-
sis and thus reduces lung morbidity [14]. Given that previous-
ly mentioned studies have shown lung and systemic disease 
from SARS-CoV-2 infection to be cytokine and immune medi-
ated, these are several possibilities by which icosapent ethyl 
can be used to modulate the course of COVID-19. Thus, per-
haps immersion pulmonary edema (IPE) shows maximum ben-
efit in patients with severe and persistent lung inflammation.
Although icosapent ethyl is not currently approved as an anti-
inflammatory treatment in patients with COVID-19, a recently 
reported case series did show some beneficial effects in reduc-
ing symptom severity [15]. Similarly, our case series describes 
3 intensive care unit (ICU) patients with moderate to severe 
COVID-19 pneumonia treated with icosapent ethyl as part of 
their supportive care who had favorable outcomes with a re-
duction in inflammatory markers. None of the patients listed 
in the following cases has been recruited to any other ongo-
ing clinical trials.
Case Reports
The following cases of SARS-CoV-2 infection were confirmed 
from a nasopharyngeal swab using the Becton Dickinson na-
sopharyngeal reverse-transcription polymerase chain reaction 
(RT-PCR) test that has received emergency use authorization 
from the U.S. Food and Drug Administration. RT-PCR testing was 
performed using Clinical Laboratory Improvement Amendments 
diagnostic standards according to current testing guidelines. 
Per guidelines, it is important that positive PCR tests be con-
firmed to avoid any false positives, whereas testing of mul-
tiple specimens/multiple body sites tested be performed to 
decrease the risk of false negatives and ensure proper sup-
portive treatment of such patients [16]. All patients in these 
cases were treated with 2 g of icosapent ethyl twice a day by 
nasogastric (NG) tube.
Case 1
A 75-year-old man with a past medical history of hyperlipid-
emia, hypertension, diabetes mellitus type 2 requiring insu-
lin, obesity, and benign prostatic hyperplasia was admitted 
to the hospital for a perirectal abscess. During admission, he 
was tested and discovered to be positive for COVID-19, and 
he confirmed subjective fever, altered mental status (memo-
ry loss and difficulty thinking), and hypoxia with chest tight-
ness. A chest X-ray demonstrated a focal right basal infiltrate 
suggestive of COVID-19 pneumonia (Figure 1). He was taken 
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to the operating room for drainage 24 h after admission to the 
hospital, and that evening he was started on icosapent ethyl 2 
g twice a day by NG tube. After the procedure, he was trans-
ferred to the ICU for hypoxia and continued systemic inflam-
matory response syndrome criteria. Two days later, he stated 
that his symptoms had totally subsided except for pain near 
the surgical site. Remarkably, his laboratory results reflect-
ed this improvement. Before treatment with icosapent ethyl, 
his creatinine was 1.43 and CRP was 23.5. After 2 days, these 
numbers improved to 1.14 and 13.6, respectively (Table 1, 
Figure 2). Additionally, he was no longer febrile, tachycardic, 
tachypneic, or hypoxic. He left the ICU after 2.5 days of treat-
ment with icosapent ethyl and antibiotics.
Case 2
On July 2. 2020, a 23-year old man with a past medical history 
of obesity and diabetes presented to the ICU with acute kidney 
injury (AKI), hypoxia, hypercapnia, respiratory failure secondary 
to COVID-19, and on noninvasive positive-pressure ventilation 
with bilevel positive airway pressure (BiPAP) with fraction of 
inspired oxygen of 100% because of acute respiratory distress 
syndrome (ARDS) along with obesity and hypoventilation that 
exacerbated COVID-19-induced hypoxia. Upon admission, the 
patient had a creatinine of 3.06. Aspartate aminotransferases 
(AST) and alanine aminotransferases (ALT) were also elevated 
at 949 U/L and 1208 U/L, respectively. On July 3 and 4, the pa-
tient was treated with tocilizumab, remdesivir, epoprostenol, 
and convalescent plasma. Acute-phase reactants began trend-
ing down on July 4. The patient was weaned off epoprostenol 
therapy on July 7, whereas he was transitioned to high-flow 
nasal cannula during daytime with BiPAP at night because of 
severe morbid obesity. Icosapent ethyl 2 g twice a day by NG 
Figure 1.  Chest X-ray findings upon admission (A) and upon leaving the intensive care unit (B) for patient in case 1.
A B
Day 1 Day 2 Day 3 Day 4
Glucose 155 142 98 89
Creatinine 1.43 1.53 1.32 1.14
Bilirubin total 1.6 0.5 0.6 0.3
CRP 23.5 13.6
Table 1. Inpatient laboratory results (case 1).
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tube was also started on this day. The patient began wean-
ing off the high-flow nasal cannula on July 8. The chest X-ray 
continued to show severe bilateral effusions and infiltrates 
consistent with ARDS (Figure 3), but because of suspect fluid 
overload, the patient was continued on Lasix for diuresis with 
tracking of fluid intake and urine output. The patient completed 
broad-spectrum antibiotics on July 9; the nephrologist signed 
off for the patient’s AKI on July 9, whereas the infectious dis-
ease specialist signed off on July 10. At the time of nephrolo-
gist sign-off, the patient had a creatinine of 0.78. AST and ALT 
were also at 18 U/L and 122 U/L, respectively. The patient pre-
sented to the hospital with AKI, presumably due to COVID-19. 
The work-up was minimal so the actual cause of AKI, given 
its rapid resolution, is not clear. Bilateral lower-extremity du-
plex scan was negative for deep vein thrombosis (DVT), de-
creasing suspicion for pulmonary embolism or venous throm-
boembolism. The patient was continued on high-intensity DVT 
prophylaxis with supportive care, a steroid course (solume-
drol), and probiotics because of frequent bowel movements. 
By July 10, chest X-rays began improving, acute-phase reac-
tants were near baseline (Table 2, Figure 4), and supportive 
care was continued. Provided these laboratory results, worsen-
ing viral load was not suspected and ARDS was suspected in 
the setting of COVID-19 pneumonia. The patient continued to 
do well on BiPAP HS and Vapotherm/high-flow nasal cannula 
during the day and displayed good diuresis. The patient was 
also having issues with hyperglycemia and had been meeting 
Figure 3.  Chest X-ray findings upon admission (A) and upon leaving the intensive care unit (B) for patient in case 2.
A B
7/3 7/4 7/5 7/6 7/7 7/8 7/9 7/10 7/12 7/24
Creatinine 1.36 1.11 1.07 0.94 0.78 0.80 0.58
ALT 949 668 418 296 216 170 122 86 69 213
AST 1208 338 107 77 40 28 18 17 14 45
LD 1784 957 832 769 635 565 462 363 283 161
Ferritin 896 596 421 376 336 347
CRP 23.1 9.1 4.1 2.1 1.1 0.6 0.8 0.4
Table 2. Inpatient laboratory results (case 2).
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with the diabetes team. The patient was removed from the ICU 
on July 14 and discharged on July 24 after 22 days.
Case 3
A 24-year old man with a past medical history of autism con-
tracted COVID-19 at his group home, and diagnosis of infec-
tion was confirmed by PCR. Subsequently, he was admitted 
to the ICU and intubated for respiratory distress. He devel-
oped ARDS in the setting of COVID-19 pneumonia on July 10. 
The patient was treated with tocilizumab, remdesivir, epopro-
stenol, dexamethasone, and convalescent plasma. Icosapent 
ethyl was given from July 11 to July 14, mistakenly discontin-
ued from July 15 to July 19, and subsequently restarted on July 
20 after he developed severe pulmonary inflammation sec-
ondary to COVID-19. Of interest, when this patient was tak-
ing icosapent ethyl as an adjunct, inflammatory markers and 
acute-phase reactants trended toward near baseline only after 
3 days of administration (Table 3, Figure 5). During the time in 
which this patient was not taking icosapent ethyl, his inflam-
matory markers increased in conjunction with his ventilatory 
requirement and he required significant supportive measures. 
In addition to broad-spectrum antibiotics, icosapent ethyl ap-
peared to be responsible for his improvement from septic 
shock, and once again, acute-phase reactants and ventilato-
ry requirements were significantly decreased in just 3.5 days. 
He was discharged to rehabilitation on August 7.
Discussion
In this clinical presentation, we have described 3 cases; in 1, a 
75-year-old patient presented for an abscess but soon devel-
oped ARDS secondary to COVID-19. Two days after administra-
tion of icosapent ethyl, inflammatory markers improved, and 
he was moved from the ICU. In the second case, a 23-year-old 
man presented with ARDS and respiratory failure also due to 
COVID-19. Inflammatory markers began trending down after 
administration of antiviral therapy, immunosuppressive ther-
apy, and convalescent plasma but the patient was still being 
considered for intubation before administration of icosapent 
ethyl. However, 3 days after the addition of icosapent ethyl 
as an adjuvant, the patient’s chest X-ray resolved, and acute-
phase reactants declined to near baseline levels. In the third 
case, a 24-year-old man was intubated for ARDS secondary 
to COVID-19. His case is notable in that he only demonstrat-
ed improvement while taking icosapent ethyl.
Icosapent ethyl, as previously stated, is indicated for the treat-
ment of persistent hypertriglyceridemia and has also been 
shown to reduce the risk of major coronary events [7]. The re-
duction in such events has been shown to occur with only a 
marginal reduction in triglyceride levels, as seen in the Japan 
EPA Lipid Intervention Study and the icosapent ethyl REDUCE-
IT trial, suggesting that the therapeutic effects may be relat-
ed to its anti-inflammatory mechanisms [17]. Indeed, a signif-
icant reduction in inflammatory markers with icosapent ethyl 
has been shown in the ANCHOR and MARINE trials with appli-
cations to a variety of other diseases including metabolic syn-
drome [11] and chronic kidney disease (CKD) [18]. Specifically, 
studies have shown that icosapent ethyl significantly lowers 











7/10 7/11 7/12 7/13 7/14 7/16 7/17 7/18 7/20 7/21 7/22 7/23 7/24 7/25 7/26 7/29
Ferritin 981 1397 1322 762 580 372 388 380 522 345 290 286 487 377 245 205
CRP 13.6 6.2 3.0 1.6 3.3 4.8 2.6 6.5 18.1 18.7 14.4 11.9 7.9 3.9
Table 3. Inpatient laboratory results (case 3).
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levels of, among other markers, hsCRP levels compared with 
placebo [11,12]. With COVID-19, prominent causes of mortality, 
including pneumonia and ARDS, have been shown to be asso-
ciated with elevated inflammatory markers including CRP, ILs, 
granulocyte colony-stimulating factors, interferons, and TNFs 
that cause pulmonary inflammation and lung damage [5,19]. 
As serum levels of cytokines have been shown to directly cor-
relate with severity of the infection in COVID-19 patients, phar-
macotherapy such as dexamethasone, corticosteroids, and IL 
antagonists such as tocilizumab have shown therapeutic ef-
fect in COVID-19 treatment [20], supporting the possibility of 
using icosapent ethyl as another potential form of treatment.
We presented 3 patients infected with SARS-CoV-2 who devel-
oped hypoxia with infiltrates on imaging, suggestive of ARDS 
secondary to COVID-19 pneumonia [21]. With icosapent ethyl 
and antibiotics alone, the 75-year-old patient improved remark-
ably, quantitively assessed by a reduction in his creatinine and 
CRP, with resolution of his tachycardia, tachypnea, and hypox-
ia. The 23-year-old benefitted initially with an immunosuppres-
sive and antiviral regimen, followed by complete resolution of 
his chest X-ray and acute-phase reactants near baseline just 3 
days after addition of icosapent ethyl. The 24-year-old showed 
improvement primarily while taking icosapent ethyl as an ad-
junct during his ICU stay. These findings were reflected in their 
laboratory results, suggesting the role of inflammation in the im-
munopathology of COVID-19 pulmonary disease and treatment.
In addition to these findings, a more recently published 2-case 
series involving a 53-year-old woman and her 21-year-old 
healthy daughter showed some similar beneficial effects of icos-
apent ethyl in reducing symptoms in COVID-19 patients [15]. 
Both the mother and the daughter had similar genetic and 
medical backgrounds and only differed in age. After exposure 
to SARS-CoV-2 and the development of similar symptoms, both 
were treated with similar symptomatic care, but only the moth-
er received icosapent ethyl. Although the mother’s symptoms 
resolved by symptom day (SD) 7, the daughter’s symptoms re-
solved only on SD18 [15]. This case series demonstrated the 
relative reduced duration of symptoms when icosapent ethyl 
was added to a treatment regimen, speaking to its anti-inflam-
matory capabilities, specifically with COVID-19 patients. With 
regard to our own cases, it is important to note that cases 2 
and 3 demonstrated more severe COVID-19 pneumonia with 
more extensive supportive treatments compared with those 
of case 1. Thus, although the actual effect of IPE is more un-
clear and difficult to interpret in these contexts, the correla-
tion between time of initiation of icosapent ethyl and rapid 
clinical improvement can be appreciated in all 3 cases. Similar 
to what was seen in the recent 2-case series, rapid improve-
ment of symptoms after icosapent ethyl administration dem-
onstrates its likely immunomodulatory effects and the immu-
nopathogenesis of COVID-19.
Conclusions
This report of 3 cases describes the use of icosapent ethyl as 
a component of supportive treatments in ICU patients with 
moderate to severe COVID-19 pneumonia. However, as of yet 
there are no evidence-based treatments for SARS-CoV-2 infec-
tion from controlled clinical trials. The outcomes of ongoing 
clinical trials are awaited to determine whether icosapent eth-
yl has anti-inflammatory effects in patients with SARS-CoV-2 
infection and which patients might benefit from the use of 
this adjunctive treatment.
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